biotech firesales Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : biotech firesales

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: biofisher who wrote (2802)	11/5/2014 1:44:39 PM
From: tuck	Read Replies (2) of 3661

Celldex (CLDX) off 17% on poor enrollment in its breast cancer trial. Company is amending the protocol, but projections for full enrollment pushed into 2016. This is, of course, a real delay, but maybe a buying op? I follow the company very loosely, so not pulling the trigger, but will dig deeper into the company, which seems to have a fair amount of cash and a fairly broad and advanced pipe. Just haven't assessed the competitive environment and likelihood their drugs might work, so just a small assignment . . . Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next